source
- Cytokinetics heart drug scores in closely watched trialMyqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.BioPharma Dive · 3mo ago↗ source
- What you need to know about hantavirus (don’t panic)The latest on the abortion pill, paternal deaths, and more health news from Morning RoundsSTAT · 3mo ago↗ source
- STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart diseaseA Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.STAT · 3mo ago↗ source